ClinicalTrials.gg
CompletedNCT00396032TROPICS 3Updated Jun 3, 2010Results posted

A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters

A Phase 3 interventional study of placebo and tenecteplase in Dysfunctional Hemodialysis Catheters, sponsored by Genentech, Inc.. Completed. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2010-06-03.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

This was a Phase III, randomized, double-blind, placebo-controlled study conducted at 37 centers in the United States. 150 subjects ≥ 16 years of age who required hemodialysis (HD) and had a dysfunctional HD catheter were enrolled in the study.

02

Conditions studied

  • Dysfunctional Hemodialysis Catheters

Browse trials for

Keywords

  • HD
  • Hemodialysis
  • Catheter clearance
  • TNKase
  • Renal Insufficiency
03

In context

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

This study's enrollment of 150 is above the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.

Browse Renal Insufficiency studies →

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically stable, in the opinion of the investigator
  • Use of a cuffed, tunneled HD catheter
  • HD prescribed at a BFR of ≥300 mL/min
  • Baseline BFR (at any time during the first 60 minutes of HD) of \<300 mL/min at an associated pre-pump negative arterial pressure in the range between and including -240 mmHg and -280 mmHg
  • Baseline BFR (at any time during the first 60 minutes of HD) at least 25 mL/min below the prescribed BFR
  • Demonstrated BFR of ≥300 mL/min (using catheter lines in the customary direction) at an arterial pressure in the range of 0 to -280 mmHg in at least one HD session in the 14 days prior to Visit 1
  • Anticipated use of the same catheter for at least four consecutive HD sessions, on the same type and model of HD apparatus
  • Able to have fluids infused at the volume necessary to instill study drug into the HD catheter

Exclusion criteria

Exclusion Criteria:

  • HD catheter with sustainable BFR of ≥300 mL/min following subject repositioning
  • HD catheter inserted \<2 days prior to screening
  • Evidence of a mechanical, non-thrombotic cause of HD catheter dysfunction (e.g., kink in the catheter or suture constricting the catheter) or dysfunction caused by known fibrin sheath
  • Use of an implantable port
  • HD catheter that is internally coated with any therapeutic agent (e.g., the Decathlon™ Gold catheter)
  • Anticipated use of catheter for any other type of diagnostic or therapeutic procedure (i.e., other than HD) during study drug treatment
  • Previously treated in this study or any tenecteplase catheter clearance trial
  • Use of any drug or therapy (defined as any drug or therapy that is not FDA approved) within 28 days prior to screening
  • Use of a fibrinolytic agent (e.g., alteplase, tenecteplase, reteplase, or urokinase) within 7 days prior to Visit 1
  • Known to be pregnant or breastfeeding at screening or at Visit 1
  • Known bacteremia or known or suspected infection in the HD catheter
  • Known history of any of the following: intracranial hemorrhage (within the previous 3 years), intracranial aneurysm, or arteriovenous malformation
  • Use of heparin (unfractionated or low molecular weight) or other anticoagulants (e.g., for the treatment of heparin-induced thrombocytopenia) within 24 hours prior to Visit 1, except for heparin used only during HD or for prophylaxis (e.g., heparin lock or deep vein thrombosis prophylaxis)
  • Subjects treated with warfarin only: (INR) >3.0 within 7 days prior to Visit 1, or a target INR range that allows for an INR >3.0 A laboratory test to confirm the INR must have been performed within 7 days prior to Visit 1.
  • Initiation of or increase in dose of Plavix® (clopidogrel bisulfate) within 7 days prior to Visit 1
  • ≥12.0 g/dL if on an erythropoiesis-stimulating agent (e.g., darbepoetin or erythropoietin) and the dose of the erythropoiesis-stimulating agent has not been held or reduced per institutional policy
  • At high risk for bleeding events or embolic complications (i.e., recent pulmonary embolus, deep vein thrombosis, endarterectomy, or right-to-left shunt) in the opinion of the investigator, or with known condition for which bleeding constitutes a significant hazard
  • BFR of \<300 mL/min because of symptomatic hypotension
  • Uncontrolled hypertension in the opinion of the investigator
  • Known to tenecteplase or any component of the formulation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    1

    Drug: tenecteplase

  • Placebo comparator
    2

    Drug: placebo

Interventions

  • Drugplacebo

    For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase

  • For the initial treatment, 2 mL of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1

    Treatment success is defined as BFR of ≥300 mL/min and an increase from baseline BFR of ≥25 mL/min at an associated target arterial pressure in the range of 0 to -280 mmHg 30 (±10) minutes prior to the end of HD and at the end of HD.

    Time frame: Visit 1 of HD treatment

  2. Incidence of Targeted Adverse Events (AEs) From Initial Study Drug Administration Through the Start of Visit 2

    Targeted AEs were intracranial hemorrhages (ICHs), major bleeding, embolic events, thrombosis, catheter-related bloodstream infections (CRBSIs), and catheter related complications

    Time frame: Visits 1 and 2 of consecutive HD treatments

Secondary outcomes

  1. Change in BFR From Baseline to the End of HD at Visit 1

    BFR is measured in mL/minute.

    Time frame: Visit 1 of HD treatment

  2. Percentage of Subjects Who Had Treatment Success With Respect to BFR at Visit 2 (MITT Population With Extended Dwell Tenecteplase at Visit 1)

    Treatment success is defined as BFR of ≥300 mL/min and an increase from baseline BFR of ≥25 mL/min at an associated target arterial pressure in the range of 0 to -280 mmHg 30 (±10) minutes prior to the end of HD and at the end of HD.

    Time frame: Visit 2 of consecutive HD treatments

  3. Percentage of Subjects Who Had Treatment Success With Respect to BFR at Visit 2 (MITT Population With Open-label Tenecteplase at Visit 2)

    Treatment success is defined as BFR of ≥300 mL/min and an increase from baseline BFR of ≥25 mL/min at an associated target arterial pressure in the range of 0 to -280 mmHg 30 (±10) minutes prior to the end of HD and at the end of HD.

    Time frame: Visit 2 of consecutive HD treatments

07

Results

Posted Jun 3, 2010

Participant flow

Participant flow — Overall Study
MilestoneTenecteplasePlacebo
Started7476
Completed7071
Not completed45

Outcome measures

PrimaryPercentage of Subjects Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1

Treatment success is defined as BFR of ≥300 mL/min and an increase from baseline BFR of ≥25 mL/min at an associated target arterial pressure in the range of 0 to -280 mmHg 30 (±10) minutes prior to the end of HD and at the end of HD.

Time frame:
Visit 1 of HD treatment
Reported as:
Number · percentage of success
Percentage of Subjects Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1
percentage of successTenecteplasePlacebo
Percentage of Subjects Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 121.65.3
Statistical analysis
  • Tenecteplase vs Placebo · Cochran-Mantel-Haenszel · p = 0.0044 (Stratified by baseline BFR: 0-199 mL/min, 200-274 mL/min, and 275-299 mL/min.)
  • Tenecteplase vs Placebo · Chi-squared · p = 0.0035
PrimaryIncidence of Targeted Adverse Events (AEs) From Initial Study Drug Administration Through the Start of Visit 2

Targeted AEs were intracranial hemorrhages (ICHs), major bleeding, embolic events, thrombosis, catheter-related bloodstream infections (CRBSIs), and catheter related complications

Time frame:
Visits 1 and 2 of consecutive HD treatments
Reported as:
Number · percentage of participants
Incidence of Targeted Adverse Events (AEs) From Initial Study Drug Administration Through the Start of Visit 2
percentage of participantsTenecteplasePlacebo
Intracranial hemorrhage00
Major bleeding00
Embolic event00
Thrombosis00
Catheter-related blood stream infection04.0
Catheter-related complication00
SecondaryChange in BFR From Baseline to the End of HD at Visit 1

BFR is measured in mL/minute.

Time frame:
Visit 1 of HD treatment
Reported as:
Number · percentage of participants
Change in BFR From Baseline to the End of HD at Visit 1
percentage of participantsTenecteplasePlacebo
< 0 mL/min8.1 ± 102.979.3 ± 55.98
0-24 mL/min58.180.0
25-49 mL/min8.12.7
50-99 mL/min8.14.0
100-149 mL/min5.41.3
Statistical analysis
  • Tenecteplase vs Placebo · Cochran-Mantel-Haenszel · p = 0.0396 (Stratified by baseline BFR: 0-199 mL/min, 200-274 mL/min, and 275-299 mL/min.)
SecondaryPercentage of Subjects Who Had Treatment Success With Respect to BFR at Visit 2 (MITT Population With Extended Dwell Tenecteplase at Visit 1)

Treatment success is defined as BFR of ≥300 mL/min and an increase from baseline BFR of ≥25 mL/min at an associated target arterial pressure in the range of 0 to -280 mmHg 30 (±10) minutes prior to the end of HD and at the end of HD.

Time frame:
Visit 2 of consecutive HD treatments
Reported as:
Number · percentage of success
Percentage of Subjects Who Had Treatment Success With Respect to BFR at Visit 2 (MITT Population With Extended Dwell Tenecteplase at Visit 1)
percentage of successTenecteplasePlacebo
Percentage of Subjects Who Had Treatment Success With Respect to BFR at Visit 2 (MITT Population With Extended Dwell Tenecteplase at Visit 1)41.738.5
SecondaryPercentage of Subjects Who Had Treatment Success With Respect to BFR at Visit 2 (MITT Population With Open-label Tenecteplase at Visit 2)

Treatment success is defined as BFR of ≥300 mL/min and an increase from baseline BFR of ≥25 mL/min at an associated target arterial pressure in the range of 0 to -280 mmHg 30 (±10) minutes prior to the end of HD and at the end of HD.

Time frame:
Visit 2 of consecutive HD treatments
Reported as:
Number · percentage of success
Percentage of Subjects Who Had Treatment Success With Respect to BFR at Visit 2 (MITT Population With Open-label Tenecteplase at Visit 2)
percentage of successTenecteplasePlacebo
Percentage of Subjects Who Had Treatment Success With Respect to BFR at Visit 2 (MITT Population With Open-label Tenecteplase at Visit 2)11.534.8

Adverse events

Collected over The AEs/SAEs were recorded through the completion of Visit 4.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tenecteplase—1/74 (1.4%)12/74 (16.2%)
Placebo—5/75 (6.7%)11/75 (14.7%)
Most frequent serious events
Most frequent serious events
EventTenecteplasePlacebo
SepsisInfections and infestations1/740/75
BacteraemiaInfections and infestations0/741/75
Clostridium Difficile ColitisInfections and infestations0/741/75
PneumoniaInfections and infestations0/741/75
HypoglycaemiaMetabolism and nutrition disorders0/741/75
ConvulsionNervous system disorders0/741/75
Most frequent other events
Showing 10 of 27
Most frequent other events
EventTenecteplasePlacebo
NauseaGastrointestinal disorders1/743/75
Thrombosis in DeviceInjury, poisoning and procedural complications2/741/75
VomitingGastrointestinal disorders1/742/75
BacteraemiaInfections and infestations0/742/75
HeadacheNervous system disorders0/742/75
Abdominal Pain UpperGastrointestinal disorders1/741/75
DiarrhoeaGastrointestinal disorders1/740/75
ChillsGeneral disorders1/741/75
PyrexiaGeneral disorders1/741/75
Catheter Related ComplicationGeneral disorders1/740/75

Baseline characteristics

Age, Customized
Age, Customized(participants)TenecteplasePlaceboTotal
< 17 years000
>= 17 years to < 65 years445195
>= 65 years302454
Age Continuous
Age Continuous(years)TenecteplasePlaceboTotal
Mean60.8 ± 14.157.8 ± 16.559.3 ± 15.3
Sex: Female, Male
Sex: Female, Male(Participants)TenecteplasePlaceboTotal
Female383775
Male363874
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Tumlin J, Goldman J, Spiegel DM, Roer D, Ntoso KA, Blaney M, Jacobs J, Gillespie BS, Begelman SM. A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3. Clin J Am Soc Nephrol. 2010 Apr;5(4):631-6. doi: 10.2215/CJN.06520909. Epub 2010 Feb 4. PubMed 20133491 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006 and a primary completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 6 months after primary completion. A results delay was requested in Jun 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2006
First posted
Nov 6, 2006
Start
Oct 2006
Primary completionActual
Dec 2008
Results delay requested
Jun 10, 2009
Results first posted
Jun 3, 2010
Last update
Jun 3, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00396032
Lead sponsor
Genentech, Inc.
First posted
Nov 6, 2006
Start date
Oct 2006
Primary completion
Dec 2008
Results posted
Jun 3, 2010
Last update
Jun 3, 2010

Study contacts

Barbara Gillespie, M.D., FASN
study director
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion